Details for Patent: 8,513,255
✉ Email this page to a colleague
Which drugs does patent 8,513,255 protect, and when does it expire?
Patent 8,513,255 protects PREVYMIS and is included in two NDAs.
This patent has forty-five patent family members in thirty-six countries.
Summary for Patent: 8,513,255
| Title: | Substituted dihydroquinazolines |
| Abstract: | The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses. |
| Inventor(s): | Wunberg; Tobias (Hinterbruehl, AT), Baumeister; Judith (Mechelen, BE), Betz; Ulrich (Reinheim, DE), Jeske; Mario (Solingen, DE), Lampe; Thomas (Duesseldorf, DE), Nikolic; Susanne (Monheim, DE), Reefschlaeger; Juergen (Oldenburg, DE), Schohe-Loop; Rudolf (Wuppertal, DE), Suessmeier; Frank (Wuppertal, DE), Zimmermann; Holger (Wuppertal, DE), Grosser; Rolf (Leverkusen, DE), Henninger; Kerstin (Wuppertal, DE), Hewlett; Guy (Haan, DE), Keldenich; Joerg (Wuppertal, DE), Lang; Dieter (Velbert, DE), Nell; Peter (Wuppertal, DE) |
| Assignee: | AiCuris GmbH + Co. KG. (Wuppertal, DE) |
| Application Number: | 11/728,896 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Process; |
Drugs Protected by US Patent 8,513,255
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-001 | Nov 8, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-002 | Nov 8, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Merck Sharp Dohme | PREVYMIS | letermovir | TABLET;ORAL | 209939-001 | Nov 8, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Merck Sharp Dohme | PREVYMIS | letermovir | TABLET;ORAL | 209939-002 | Nov 8, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,513,255
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 103 19 612 | May 2, 2003 |
International Family Members for US Patent 8,513,255
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 044078 | ⤷ Try a Trial | |||
| Austria | 355280 | ⤷ Try a Trial | |||
| Australia | 2004233978 | ⤷ Try a Trial | |||
| Brazil | PI0410029 | ⤷ Try a Trial | |||
| Canada | 2524069 | ⤷ Try a Trial | |||
| Chile | 2004000930 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
